BioCentury
ARTICLE | Clinical News

July 10 Clinical Quick Takes: Darzalex quad combo raises MM complete response, plus Geneos and ViiV

July 10, 2019 10:41 PM UTC

Adding Darzalex improves MM complete response rate in Phase II
Genmab A/S (CSE:GEN; Pink:GMXAY) said Darzalex daratumumab in combination with Revlimid lenalidomide, Velcade bortezomib and dexamethasone met the primary endpoint in the Phase II GRIFFIN (MMY2004) trial to treat newly diagnosed multiple myeloma patients who are candidates for autologous stem cell transplant (ASCT). The quadruple combination led to a 42.4% stringent complete response rate vs. 32% for a triple combination lacking Darzalex (odds ratio=1.57, 95% CI: 0.87, 2.82, p=0.139 with statistical significance pre-set at a 2-sided α level of 0.2).The Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) holds worldwide rights to Darzalex, which is approved in the indication for patients ineligible for ASCT.

First patient dosed with Geneos' personalized vaccine under compassionate use
Inovio Pharmaceuticals Inc. (NASDAQ:INO) spinout Geneos Therapeutics Inc. (Plymouth Meeting, Pa.) announced that under compassionate use, an anaplastic astrocytoma patient has become the first to receive a DNA-based neoantigen-targeting vaccine. The vaccine, designed with Geneos' GT-EPIC platform, targets 27 neoantigens and three tumor antigens in the patient's tumor...